- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02573571
Personalized Needs in Clostridium Difficile Infections (SPECIFY)
Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Medical world is nowadays witnessing a sudden increase of the incidence of infections by Clostridium difficile (DCI). This is due in part to the prolongation of survival of patients with major comorbidities like solid tumor malignancies and lymphomas but also to the widespread intake of proton pump inhibitors and of wide-spectrum antimicrobials. It is highly probable that isolates of C.define causing this pandemic are genetically different than isolates of the same species predominating 20 years ago. This hypothesis is developed based on data of the epidemiology of CDI: in old times administration of clindamycin and ampicillin were the main drivers of CDI; recent studies report fluoroquinolones, 2nd and 3rd generation cephalosporins and even vancomycin (i.e. a drug of choice for CDI) to be linked with the development of CDI.
One major hurdle in management of CDI is relapse; the risk of relapse is reported as 15-20% after the first episode; however it is geometrically increased to even 60-80% after the second episode. As a consequence, management of CDI becomes a major health problem.
Fidaxomicin is a novel compound active against species of C.dificille. Results of two recent double-blind, randomized, large scale clinical studies have shown that oral treatment for 10 days with fidaxomicin 200mg bid was non-inferior to oral treatment with vancomycin 125mg q6h. However, the risk of relapse after treatment with vancomycin was close to 25% and with fidaxomicin close to 15%. This difference was statistically significant in both trials outscoring the superiority of fidaxomicin over vancomycin for the management of CDI. Moreover, meta-analysis has shown a significant reduction in mortality by fidaxomicin.
Despite proven superiority, prescription of fidaxomicin is limited to few cases mostly due to high cost. In many countries prescription is restricted to cases of relapsing CDI. Clinical feeling coming both from post-marketing experience as well as from published evidence supports the use of fidaxomicin for cases with risk of death and overt risk of relapse. However, molecular analysis of the C.difficile pathogen cannot be used as a tool for the prediction of relapse since in relapse cases pathogens carry less than 2 single nucleotide variants of the initial isolate. SPECIFY is aiming to develop a score using both clinical and genetic and biomarker data that can efficiently discriminate patients at risk of severe CDI and at risk of relapse of CDI. This score can become in future a tool to discriminate patients at need for treatment with fidaxomicin instead of traditional treatment with metronidazole/vancomycin.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Athens, Grécia, 10676
- 5th Department of Internal Medicine, Evangelismos Athens General Hospital
-
Athens, Grécia, 11527
- 1st Department of Internal Medicine, "G.Gennimatas" General hospital
-
Athens, Grécia, 11527
- 1st Department of Internal Medicine, Laikon General Hospital
-
Athens, Grécia, 11527
- 3rd Department of Internal Medicine, Sotiria General Hospital
-
Athens, Grécia, 12462
- 4th Department of Internal Medicine, Attikon University Hospital
-
Athens, Grécia, 15126
- 2nd Department of Internal Medicine, Sismanogleion General Hospital
-
Magoula, Grécia, 10918
- 1st Department of Internal Medicine, Thriassio General Hospital
-
Magoula, Grécia, 10918
- 2nd Department of Internal Medicine, Thriasio General Hospital
-
Maroúsi, Grécia, 15123
- 2nd Department of Oncology, Mitera Hospital
-
Piraeus, Grécia
- Infections Unit Tzaneion General Hospital
-
Pátra, Grécia, 36504
- Department of Internal Medicine, Patras University Hospital
-
Thessaloniki, Grécia, 54248
- 1st Department of Internal Medicine, AHEPA University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age equal to or more than 18 years
- Both genders
- Diarrhea defined as at least 3 episodes of unformed stools in the last 24 hours according to the Bristol stool chart
- Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.
Exclusion Criteria:
1. No exclusion criteria exist
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Caso-somente
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
Clostridium difficile infection
Patients with Clostridium difficile-associated diarrhea for development of biomarkers
|
Blood sampling
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Definition of prognostic biomarker
Prazo: 12 months
|
Patients with positive score and unfavorable outcome.
Unfavorable outcome is defined as at least one of the following: a) number of patients with severe infection at disease onset; b) number of patients who progress into severe infection; c) number of patients with disease recurrence; and d) number of patients who die
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Athanasios Skoutelis, MD, Evangelismos Athens General Hospital
- Cadeira de estudo: Evangelos J Giamarellos-Bourboulis, MD, PhD, Attikon Hospital
- Investigador principal: George Chrysos, MD, PhD, Tzaneion Piraeus General Hospital
- Investigador principal: Styliani Symbardi, MD, PhD, Thriassio Elefsis General Hospital
- Investigador principal: Zoi Alexiou, MD, PhD, Thriassio Elefsis General Hospital
- Investigador principal: Kostantinos Syrigos, MD, PhD, Sotiria General Hospital
- Investigador principal: George Daikos, MD, PhD, Laikon Athens General Hospital
- Investigador principal: Panagiotis Gargalianos, MD, PhD, G.Gennimatas Athens General Hospital
- Investigador principal: Malvina Lada, MD, PhD, Sismanogleion General Hospital
- Investigador principal: Charalambos Gogos, MD, PhD, University Hospital of Patras
- Investigador principal: Ilias Athanasiadis, MD, PhD, Mitera General Hospital
- Investigador principal: Symeon Metallidis, MD, PhD, AHEPA Thessaloniki University Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CL01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Development of biomarkers
-
ORIOL BESTARDConcluídoTransplante Renal | Infecção por CMVEspanha, Bélgica
-
Gazi UniversityConcluídoExposição Ambiental | Desenvolvimento infantil | PrematuroPeru
-
Hacettepe UniversityConcluídoDoenças musculoesqueléticas | Doença genética | Doença Metabólica | Atrasa o DesenvolvimentoPeru
-
Augusta UniversityRecrutamentoErupção passiva alterada dos dentesEstados Unidos
-
WellSpan HealthStony Brook University; University of California, IrvineRecrutamentoEmbolia pulmonarEstados Unidos
-
Loma Linda UniversityRecrutamentoUltrassom Point of Care | Hemorragia Digestiva Alta | Conteúdo Gástrico | Endoscopia Alta | Sangramento gastrointestinalEstados Unidos
-
Sakarya UniversityConcluído
-
Yale UniversityConcluídoSepse | HipotensãoEstados Unidos
-
University of BurgundyConcluído
-
Karolinska InstitutetConcluídoDerrame | Afasia | Apraxia de falaSuécia